

S2 Table. Patient characteristics of the prematched cohort (n=97)

	Prematched (n=97)			Post-matched (n=66)		
	No mutation (n=64)	Mutation present (n=33)	p-value	No mutation (n=33)	Mutation present (n=33)	p-value
Age (yr)	55 (28-80)	54 (23-71)	0.351	53 (28-72)	54 (23-71)	0.949
Sex			0.504			>0.99
Male	19 (29.7)	12 (36.4)		12 (36.4)	12 (36.4)	
Female	45 (70.3)	21 (63.6)		21 (63.6)	21 (63.6)	
Radiosensitivity according to primary site and histology ^{a)}			0.087			>0.99
Sensitive	51 (79.7)	21 (63.6)		21 (63.6)	21 (63.6)	
Resistant	13 (20.3)	12 (36.4)		12 (36.4)	12 (36.4)	
Pre-RT chemotherapy			0.780			0.314
Cytotoxic chemotherapy	44 (68.8)	24 (72.7)		27 (81.8)	24 (72.7)	
Target agents	11 (17.2)	6 (18.2)		2 (6.1)	6 (18.2)	
None	9 (14.1)	3 (9.1)		4 (12.1)	3 (9.1)	
EQD2 (Gy)			0.996			0.323
< 45	33 (51.6)	17 (51.5)		13 (39.4)	17 (51.5)	
≥ 45	31 (48.4)	16 (48.5)		20 (60.6)	16 (48.5)	
RT modality			0.819			0.807
Conventional	17 (26.6)	10 (30.3)		10 (30.3)	10 (30.3)	
Hypofractionated	41 (64.1)	21 (63.6)		19 (57.6)	21 (63.6)	
SBRT	6 (9.4)	2 (6.1)		4 (12.1)	2 (6.1)	

Values are presented as mediana (range) or number (%). EQD2, equivalent dose in 2 Gy; RT, radiotherapy; SBRT, stereotactic body radiation therapy. ^{a)}Radiosensitive: Breast, lung, ovary; Radioresistant: GI tract, melanoma.